COVID-19 and Cirrhosis: A Combination We Must Strive to Prevent.
作者信息
Su Feng
机构信息
Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, Virginia.
出版信息
Gastroenterology. 2021 Nov;161(5):1371-1373. doi: 10.1053/j.gastro.2021.08.037. Epub 2021 Aug 25.
Abstract
摘要
相似文献
1
COVID-19 and Cirrhosis: A Combination We Must Strive to Prevent.
Gastroenterology. 2021 Nov;161(5):1371-1373. doi: 10.1053/j.gastro.2021.08.037. Epub 2021 Aug 25.
2
Correspondence on "prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection".
Ann Hepatol. 2021 Nov-Dec;25:100360. doi: 10.1016/j.aohep.2021.100360. Epub 2021 Jun 10.
3
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study).
Hepatol Int. 2020 Sep;14(5):690-700. doi: 10.1007/s12072-020-10072-8. Epub 2020 Jul 4.
4
Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19.
Gut. 2021 Sep;70(9):1798-1799. doi: 10.1136/gutjnl-2020-322929. Epub 2020 Oct 7.
5
SARS-CoV-2 infection in patients with a normal or abnormal liver.
J Viral Hepat. 2021 Jan;28(1):4-11. doi: 10.1111/jvh.13440. Epub 2020 Dec 1.
6
COVID-19: a fatal case of acute liver failure associated with SARS-CoV-2 infection in pre-existing liver cirrhosis.
BMC Infect Dis. 2021 Sep 3;21(1):901. doi: 10.1186/s12879-021-06605-7.
7
Mortality Trends in Chronic Liver Disease and Cirrhosis in the United States, Before and During COVID-19 Pandemic.
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2664-2666.e2. doi: 10.1016/j.cgh.2021.07.009. Epub 2021 Jul 10.
8
COVID-19 in patients with cirrhosis: understanding adverse impact.
Gut. 2021 Jul;70(7):1409. doi: 10.1136/gutjnl-2020-322561. Epub 2020 Aug 21.
9
Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection.
Ann Hepatol. 2021 Nov-Dec;25:100350. doi: 10.1016/j.aohep.2021.100350. Epub 2021 Apr 14.
10
Letter regarding "High rates of 30-day mortality in patients with cirrhosis and COVID-19".
J Hepatol. 2020 Dec;73(6):1569-1570. doi: 10.1016/j.jhep.2020.06.023. Epub 2020 Jun 20.
引用本文的文献
1
COVID-19, Possible Hepatic Pathways and Alcohol Abuse-What Do We Know up to 2023?
Int J Mol Sci. 2024 Feb 12;25(4):2212. doi: 10.3390/ijms25042212.
2
Evaluation of the effects of the pandemic period on cirrhosis patients.
Prz Gastroenterol. 2023;18(3):320-326. doi: 10.5114/pg.2023.131393. Epub 2023 Sep 22.
3
Risk of New-Onset Liver Injuries Due to COVID-19 in Preexisting Hepatic Conditions-Review of the Literature.
Medicina (Kaunas). 2022 Dec 28;59(1):62. doi: 10.3390/medicina59010062.
4
Liver injury in COVID-19: A minireview.
World J Gastroenterol. 2022 Dec 21;28(47):6716-6731. doi: 10.3748/wjg.v28.i47.6716.
5
COVID-19 vaccines in patients with decompensated cirrhosis: a retrospective cohort on safety data and risk factors associated with unvaccinated status.
Infect Dis Poverty. 2022 May 16;11(1):56. doi: 10.1186/s40249-022-00982-0.
本文引用的文献
1
Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study.
Gastroenterology. 2021 Nov;161(5):1487-1501.e5. doi: 10.1053/j.gastro.2021.07.010. Epub 2021 Jul 18.
2
Association of BNT162b2 mRNA and mRNA-1273 Vaccines With COVID-19 Infection and Hospitalization Among Patients With Cirrhosis.
JAMA Intern Med. 2021 Oct 1;181(10):1306-1314. doi: 10.1001/jamainternmed.2021.4325.
3
Impact of the Coronavirus Disease 2019 Pandemic on Gastrointestinal Procedures and Cancers in the United States: A Multicenter Research Network Study.
Gastroenterology. 2021 Jun;160(7):2602-2604.e5. doi: 10.1053/j.gastro.2021.02.055. Epub 2021 Mar 1.
4
Changes in Hepatocellular Carcinoma Surveillance and Risk Factors for Noncompletion in the Veterans Health Administration Cohort During the Coronavirus Disease 2019 Pandemic.
Gastroenterology. 2021 May;160(6):2162-2164.e3. doi: 10.1053/j.gastro.2021.01.007. Epub 2021 Jan 9.
5
Socioeconomic Factors Contribute to the Higher Risk of COVID-19 in Racial and Ethnic Minorities With Chronic Liver Diseases.
Gastroenterology. 2021 Mar;160(4):1406-1409.e3. doi: 10.1053/j.gastro.2020.11.035. Epub 2020 Nov 20.
6
Cirrhosis and Severe Acute Respiratory Syndrome Coronavirus 2 Infection in US Veterans: Risk of Infection, Hospitalization, Ventilation, and Mortality.
Hepatology. 2021 Jul;74(1):322-335. doi: 10.1002/hep.31649. Epub 2021 Jun 2.
7
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study.
J Hepatol. 2021 Mar;74(3):567-577. doi: 10.1016/j.jhep.2020.09.024. Epub 2020 Oct 6.
8
Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study.
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1469-1479.e19. doi: 10.1016/j.cgh.2020.09.027. Epub 2020 Sep 17.
9
Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort.
Gut. 2021 Mar;70(3):531-536. doi: 10.1136/gutjnl-2020-322118. Epub 2020 Jul 13.
10
Declining Cirrhosis Hospitalizations in the Wake of the COVID-19 Pandemic: A National Cohort Study.
Gastroenterology. 2020 Sep;159(3):1134-1136.e3. doi: 10.1053/j.gastro.2020.05.005. Epub 2020 May 6.
Zotero 插件